Jared Weiss, MD
Hematology & Oncology · Chapel Hill, NCNPI 1376577130
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $167,963 of the $217,121 with a category attached, or 77.4%. It is spread thinly across 34 manufacturers, the largest accounting for just 15.9%. Reporting peaked in 2019 at $51,414 and has fallen 74.7% since, to $13,011 in 2025. Among hematology & oncology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 148 payments — averaging $1467.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$34K
- EMD Serono, Inc.$24K
- G1 Therapeutics, Inc.$20K
- Pfizer$19K
- Genentech USA, Inc.$15K
- Eli Lilly$13K
- plus $91K from 28 others
Across 304 payments — averaging $23,266 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3.3M
- Merck$905K
- Mirati Therapeutics, Inc.$796K
- AstraZeneca$710K
- Astrazeneca UK Limited$392K
- Amgen$357K
- plus $579K from 11 others
What the payments were for
- Consulting fees$167,96377%
- Speaking & faculty fees$41,65219%
- Travel & lodging$4,5542%
- Food & beverage$2,9391%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $34,464 |
| EMD Serono, Inc. | 8 | $24,295 |
| G1 Therapeutics, Inc. | 6 | $20,499 |
| Pfizer | 13 | $19,351 |
| Genentech USA, Inc. | 11 | $14,509 |
| Eli Lilly | 26 | $13,412 |
| AbbVie | 7 | $11,979 |
| Beigene, Ltd. | 5 | $11,700 |
| Merck | 11 | $8,541 |
| Amgen | 6 | $6,332 |
| Jazz Pharmaceuticals Inc. | 2 | $5,650 |
| Boehringer Ingelheim International GmbH | 5 | $5,444 |
| GSK | 7 | $5,251 |
| Sanofi | 2 | $4,454 |
| Astrazeneca UK Limited | 3 | $4,126 |
| Daiichi Sankyo Inc. | 1 | $4,110 |
| Janssen Research & Development, LLC | 1 | $4,050 |
| Gilead | 3 | $3,247 |
| Catalyst Pharmaceuticals, Inc. | 2 | $2,372 |
| Bristol Myers Squibb | 1 | $2,260 |
| E.r. Squibb & Sons, L.L.C. | 1 | $2,000 |
| Regeneron | 1 | $1,575 |
| Genentech, Inc. | 1 | $1,535 |
| Ipsen Innovation | 1 | $1,470 |
| Ares Trading SA | 1 | $1,425 |
| Dr.reddy's Laboratories,inc. | 1 | $999 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $884 |
| Genmab U.S., Inc. | 5 | $516 |
| Pharmacosmos Therapeutics Inc. | 1 | $259 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $190 |
| Ventana Medical Systems, Inc. | 1 | $114 |
| Astrazeneca AB | 2 | $51 |
| Johnson & Johnson | 1 | $43 |
| Iovance Biotherapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$217,121 in reported general payments places this provider in the 95th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 46 | $724,611 |
| EliquisApixaban | 17 | $12,164 |
| Minocycline Hcl | 19 | $497 |
| Prochlorperazine Maleate | 24 | $438 |
| Dexamethasone | 18 | $333 |
| Levothyroxine Sodium | 84 | $275 |
| Ondansetron Hcl | 34 | $274 |
| Olanzapine | 25 | $220 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $34,464 | $724,61146 claims |
| PfizerEliquis | $19,351 | $12,16417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 358 hematology & oncology providers in North Carolina.
Other hematology & oncology in Chapel Hill
- Joshua ZeidnerChapel Hill$208K
- Brandi ReevesChapel Hill$198K
- Nigel KeyChapel Hill$174K
- Norman SharplessChapel Hill$125K
- Lisa CareyChapel Hill$51K
- Alice MaChapel Hill$42K
- Thomas SheaChapel Hill$24K
- Juneko Grilley OlsonChapel Hill$24K
- Amit MehtaCary$4.3M
- Michael MorseDurham$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.